{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:04:12Z","timestamp":1793117052950,"version":"4.5.0"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"\n Importance<\/jats:title>\n Glucagon-like peptide\u20131 receptor agonists can reduce the risk of cardiovascular events in patients with high-risk type 2 diabetes (T2D). However, dedicated randomized clinical trials that evaluate their efficacy in acute ischemic stroke are lacking.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To investigate the safety and efficacy of liraglutide in patients with T2D and minor acute ischemic stroke (AIS) or high-risk transient ischemic attack (TIA).<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n The LAMP trial was designed as a multicenter, controlled, prospective, randomized, open-label, blinded end point trial and conducted at 27 hospitals in China from June 25, 2019, through December 27, 2023. The final follow-up was on March 24, 2024. Data were analyzed on May 1, 2024. The study included patients with T2D who had minor AIS (National Institutes of Health Stroke Scale score \u22643) or high-risk TIA (ABCD\n 2<\/jats:sup>\n score [age, blood pressure elevation on first assessment after TIA, unilateral weakness, speech disturbance, duration of symptoms and diabetes] \u22654).\n <\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Eligible patients were randomized within 24 hours of symptom onset to the liraglutide group and the control group. Both groups received standard treatment according to the guidelines. The liraglutide group received liraglutide once daily for 90 days (0.6 mg for the first week, which was increased to 1.2 mg in the second week and followed by 1.8 mg until day 90) in addition to standard therapy.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was stroke recurrence (ischemic or hemorrhagic) after 90 days, and the safety outcome was symptomatic intracranial hemorrhage and all-cause mortality at 90 days.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n In all, 636 patients (median [IQR] age, 63.5 [57.8-70.0] years; 231 female individuals [36.3%]) were randomized. Within 90 days, 25 patients (7.9%) in the liraglutide group and 44 (13.8%) in the control group experienced stroke recurrence (hazard ratio, 0.56; 95% CI, 0.34-0.91;\n P<\/jats:italic>\n \u2009=\u2009.02). A significantly higher proportion of patients (modified Rankin Scale score, \u22641) in the liraglutide group (274 [87.3%]) than in the control group (246 [77.8%]) achieved excellent functional outcomes (odds ratio, 1.95; 95% CI, 1.28-3.00;\n P<\/jats:italic>\n \u2009=\u2009.002). The rates of symptomatic intracranial hemorrhage and all-cause mortality were low and similar between the groups.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The trial results suggest that among Chinese patients with T2D and minor AIS or high-risk TIA, liraglutide treatment might reduce stroke recurrence and improve 90-day outcomes. However, given the underpowered nature of the study, these findings should be interpreted with caution.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT03948347<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamainternmed.2025.5684","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:01:39Z","timestamp":1762185699000},"page":"46","source":"Crossref","is-referenced-by-count":18,"title":["Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack With Type 2 Diabetes"],"prefix":"10.1001","volume":"186","author":[{"given":"Huili","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Neurology, the First Affiliated Hospital of Jinan University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurology, the First Affiliated Hospital of Jinan University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longyan","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Neurology, the First Affiliated Hospital of Jinan University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, the First Affiliated Hospital of Jinan University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubo","family":"Sui","sequence":"additional","affiliation":[{"name":"Department of Neurology, the First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kewei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, People\u2019s Hospital of Longmen County, Longmen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suling","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Neurology, People\u2019s Hospital of Xinfeng County, Xinfeng, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, the Second Affiliated Hospital of Harbin Medical University, Harbin. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Neurology, the First Hospital of Putian, Putian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbin","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Neurology, the Fourth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongguo","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Neurology, Meizhou People\u2019s Hospital, Meizhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhang","family":"Bei","sequence":"additional","affiliation":[{"name":"Department of Neurology, Liuyang Jili Hospital, Liuyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Affiliated Hospital of Youjiang Medical College for Nationalities, Baise, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suping","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Guangzhou Red Cross Hospital, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Neurology, Guangdong Clifford Hospital, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Zhongshan People\u2019s Hospital, Zhongshan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youjia","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, the First People\u2019s Hospital of Zhaoqing, Zhaoqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Neurology, the First Affiliated Hospital of Gannan Medical College, Ganzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangkun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Dongguan People\u2019s Hospital, Dongguan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Houjie Hospital, Dongguan City, Dongguan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyong","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ganzhou people\u2019s Hospital, Ganzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, the First Affiliated Hospital of Jinan University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Neurology, the First Affiliated Hospital of Jinan University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Li","sequence":"additional","affiliation":[{"name":"Beijing Tiantan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangbing","family":"Wang","sequence":"additional","affiliation":[{"name":"Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Wang","sequence":"additional","affiliation":[{"name":"Beijing Tiantan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anding","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Neurology, the First Affiliated Hospital of Jinan University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"LAMP Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Yan","family":"Zhuo","sequence":"additional","affiliation":[{"name":"for the LAMP Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Yu","family":"Shen","sequence":"additional","affiliation":[{"name":"for the LAMP Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Xia","sequence":"additional","affiliation":[{"name":"for the LAMP Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Gang","family":"Cha","sequence":"additional","affiliation":[{"name":"for the LAMP Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang-Ping","family":"Luo","sequence":"additional","affiliation":[{"name":"for the LAMP Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan-Yu","family":"Cai","sequence":"additional","affiliation":[{"name":"for the LAMP Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Dong","family":"Zhang","sequence":"additional","affiliation":[{"name":"for the LAMP Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Ming","family":"Liu","sequence":"additional","affiliation":[{"name":"for the LAMP Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhou","sequence":"additional","affiliation":[{"name":"for the LAMP Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Min","family":"Xiao","sequence":"additional","affiliation":[{"name":"for the LAMP Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-Ping","family":"Liu","sequence":"additional","affiliation":[{"name":"for the LAMP Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Ping","family":"Jiang","sequence":"additional","affiliation":[{"name":"for the LAMP Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ju","family":"Chen","sequence":"additional","affiliation":[{"name":"for the LAMP Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Qiao","family":"Li","sequence":"additional","affiliation":[{"name":"for the LAMP Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Song","family":"Wu","sequence":"additional","affiliation":[{"name":"for the LAMP Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Xia","family":"Wu","sequence":"additional","affiliation":[{"name":"for the LAMP Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Hua","family":"Chen","sequence":"additional","affiliation":[{"name":"for the LAMP Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ping","family":"Qiu","sequence":"additional","affiliation":[{"name":"for the LAMP Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Hua","family":"Chen","sequence":"additional","affiliation":[{"name":"for the LAMP Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[{"name":"for the LAMP Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Zheng","sequence":"additional","affiliation":[{"name":"for the LAMP Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wang","sequence":"additional","affiliation":[{"name":"for the LAMP Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Xin","family":"Wang","sequence":"additional","affiliation":[{"name":"for the LAMP Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Lv","sequence":"additional","affiliation":[{"name":"for the LAMP Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Sheng","family":"Li","sequence":"additional","affiliation":[{"name":"for the LAMP Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang-Ning","family":"Chen","sequence":"additional","affiliation":[{"name":"for the LAMP Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Hu","sequence":"additional","affiliation":[{"name":"for the LAMP Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Shun","family":"Zhang","sequence":"additional","affiliation":[{"name":"for the LAMP Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao-Wei","family":"Li","sequence":"additional","affiliation":[{"name":"for the LAMP Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Jian","family":"Xie","sequence":"additional","affiliation":[{"name":"for the LAMP Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Liang","sequence":"additional","affiliation":[{"name":"for the LAMP Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen-Wen","family":"He","sequence":"additional","affiliation":[{"name":"for the LAMP Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"ioi250067r1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"ioi250067r2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1136\/svn-2021-000885","article-title":"Residual recurrence risk of ischaemic cerebrovascular events: concept, classification and implications.","volume":"6","author":"Wang","year":"2021","journal-title":"Stroke Vasc Neurol"},{"issue":"9733","key":"ioi250067r3","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"ioi250067r4","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/jdi.12932","article-title":"Prevalence of diabetes and its effects on stroke outcomes: A meta-analysis and literature review.","volume":"10","author":"Lau","year":"2019","journal-title":"J Diabetes Investig"},{"issue":"15","key":"ioi250067r5","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1212\/WNL.0000000000003200","article-title":"Abnormal glucose regulation increases stroke risk in minor ischemic stroke or TIA.","volume":"87","author":"Pan","year":"2016","journal-title":"Neurology"},{"issue":"9131","key":"ioi250067r6","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).","volume":"352","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"Lancet"},{"issue":"24","key":"ioi250067r7","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"issue":"7","key":"ioi250067r8","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1210\/endo.137.7.8770921","article-title":"Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor.","volume":"137","author":"Bullock","year":"1996","journal-title":"Endocrinology"},{"issue":"10","key":"ioi250067r9","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"ioi250067r10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"ioi250067r11","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"10193","key":"ioi250067r12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"ioi250067r13","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12933-022-01686-3","article-title":"Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms.","volume":"21","author":"Verg\u00e8s","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"7742","key":"ioi250067r14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41586-018-0849-9","article-title":"Gut intraepithelial T cells calibrate metabolism and accelerate cardiovascular disease.","volume":"566","author":"He","year":"2019","journal-title":"Nature"},{"issue":"9","key":"ioi250067r15","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes.","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"key":"ioi250067r16","doi-asserted-by":"publisher","first-page":"26859","DOI":"10.1038\/srep26859","article-title":"The neuroprotection of liraglutide against ischaemia-induced apoptosis through the activation of the PI3K\/AKT and MAPK pathways.","volume":"6","author":"Zhu","year":"2016","journal-title":"Sci Rep"},{"issue":"3","key":"ioi250067r17","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1177\/1747493017694391","article-title":"2014 Chinese guidelines for secondary prevention of ischemic stroke and transient ischemic attack.","volume":"12","author":"Wang","year":"2017","journal-title":"Int J Stroke"},{"issue":"1","key":"ioi250067r18","first-page":"4","article-title":"Chinese guideline for the prevention and treatment of type 2 diabetes mellitus (2017 edition).","volume":"10","author":"Chinese Medical Association Diabetes Branch","year":"2018","journal-title":"Chin J Diabetes Mellitus"},{"issue":"3","key":"ioi250067r19","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1161\/STR.0000000000000158","article-title":"2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association.","volume":"49","author":"Powers","year":"2018","journal-title":"Stroke"},{"issue":"9136","key":"ioi250067r20","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0140-6736(98)08020-9","article-title":"Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II).","volume":"352","author":"Hacke","year":"1998","journal-title":"Lancet"},{"issue":"3","key":"ioi250067r21","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1161\/STROKEAHA.119.027465","article-title":"Disability after minor stroke and transient ischemic attack in the POINT trial.","volume":"51","author":"Cucchiara","year":"2020","journal-title":"Stroke"},{"issue":"1","key":"ioi250067r22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2337\/db23-0356","article-title":"Weight loss\u2013independent effect of liraglutide on insulin sensitivity in individuals with obesity and prediabetes.","volume":"73","author":"Mashayekhi","year":"2024","journal-title":"Diabetes"},{"issue":"14","key":"ioi250067r23","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack.","volume":"374","author":"Kernan","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"ioi250067r24","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s10557-013-6463-z","article-title":"Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation.","volume":"27","author":"Dai","year":"2013","journal-title":"Cardiovasc Drugs Ther"},{"issue":"9","key":"ioi250067r25","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.2337\/db15-0084","article-title":"GLP-1 cleavage product reverses persistent ROS generation after transient hyperglycemia by disrupting an ROS-generating feedback loop.","volume":"64","author":"Giacco","year":"2015","journal-title":"Diabetes"},{"issue":"9","key":"ioi250067r26","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s00125-017-4330-3","article-title":"The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype.","volume":"60","author":"Vinu\u00e9","year":"2017","journal-title":"Diabetologia"},{"issue":"6","key":"ioi250067r27","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2337\/dbi16-0014","article-title":"Glucagon-like peptide 1 receptor activation and platelet function: beyond glycemic control.","volume":"65","author":"Jia","year":"2016","journal-title":"Diabetes"},{"issue":"1","key":"ioi250067r28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12933-021-01366-8","article-title":"GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs.","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"ioi250067r29","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.mayocp.2018.08.007","article-title":"Cardiovascular disease in type 2 diabetes: a review of sex-related differences in predisposition and prevention.","volume":"94","author":"Al-Salameh","year":"2019","journal-title":"Mayo Clin Proc"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2840370\/jamainternal_zhu_2025_oi_250067_1766507966.00854.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T16:01:05Z","timestamp":1767628865000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2840370"}},"subtitle":["The LAMP Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2025.5684","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,1]]}}}